Alteplase for Posterior Circulation Ischemic Stropke at 4.5 to 24 Hours
NEJM 392:1288-1296, Yan,S.,et al, 2025
Tenecteplase for Stroke - Opening the Window?
NEJM 390:760-761, Leifer,D.,, 2024
Thrombectomy versus Medical Management in Mild Strokes due to Large Vessel Occlusion: Exploratory Analysis from the EXTEND-IA Trials and a Pooled International Cohort
Ann Neurol 92:364-378, Sarraj, A.,et al, 2022
Intravenous Thrombolysis with Tenecteplase for the Treatment of Acute Ischemic Stroke
Ann Neurol 92:349-357, Tsivgoulis, G.,et al, 2022
Thrombectomy and Thrombolysis of Isolated Posterior Cerebral Artery Occlusion
Stroke 51:254-261, Strambo, D.,et al, 2020
Thrombolysis for Acute Ischemic Stroke in the Unwitnessed or Extended Therapeutic Time Window
Neurol 94:e1241-e1248, Tsivgoulis, G.,et al, 2020
Stroke Reperfusion Therapy Following Dabigatran Reversal with Idarucizumab in a National Cohort
Neurol 94:e1968-e1972, Barber, P.A.,et al, 2020
Intravenous Alteplase for Stroke with Unknown Time of Onset Guided by Advanced Imaging:Systematic Review and Meta-Analysis of Individual Patient Data
Lancet 396:1574-1585, Thomalla,G.,et al, 2020
Thrombolysis Guided by Perfusion Imaging up to 9 Hours after Onset of Stroke
NEJM 380:1795-1803,1865, Ma, H.,et al, 2019
Tenecteplase versus Alteplase before Thrombectomy for Ischemic Stroke
NEJM 378:1573-1582, Campbell, B.C.V.,et al, 2018
MRI-Guided Thrombolysis for Stroke with Unknown Time of Onset
NEJM 379:611-622, 682, Thomalla, G.,et al, 2018
Intravenous Thrombolysis in Unwitnessed Stroke Onset: MR WITNESS Trial Results
Ann Neurol 83:980-993, Schwamm, L.H.,et al, 2018
Coexistent Sickle Cell Disease has No Impact on the Safety or Outcome of Lytic Therapy in Acute Ischemic Stroke
Stroke 48:686-691, Adams, R.J.,et al, 2017
Favorable Bridging Therapy Based on DWI-FLAIR Mismatch in Patients with Unclear-Onset Stroke
AJNR 37:88-93, Mourand, I.,et al, 2016
Effects of Golden Hour Thrombolysis
JAMA Neurol 72:25-30,9, Ebinger, M.,et al, 2015
Thrombectomy within 8 Hours after Symptom Onset in Ischemic Stroke
NEJM 372:DOI:10.1056 NEJMoa1503780, DOI:1056NEJM e1503217, Jovin, T.G.,et al, 2015
Endovascular Therapy is Effective and Safe for Patients with Severe Ischemic Stroke
Stroke 46:3416-3422, Broderick, J.P.,et al, 2015
Endovascular vs Medical Management of Acute Ischemic Stroke
Neurol 85:1980-1990, Chen, C.J.,et al, 2015
Prehospital Thrombolysis in Acute Stroke
Neurol 80:163-168, Weber, J.,et al, 2013
An Observational Study of Thrombolysis Outcomes in Wake-Up Ischemic Stroke Patients
Stroke 44:427-431, Manawadu, D.,et al, 2013
Endovascular Treatment for Acute Ischemic Stroke-Still Unproven
NEJM 368:952-955, Chimowitz,M., 2013
A Trial of Imaging Selection and Endovascular Treatment for Ischemic Stroke
NEJM 368:914-923,952, Kidwell, C.S.,et al, 2013
Endovascular Therapy after Intravenous t-PA versus t-PA Alone for Stroke
NEJM 368:893-903,952, Broderick, J.P.,et al, 2013
Endovascular Treatment for Acute Ischemic Stroke
NEJM 368:914-923,952, Ciccone, A.,et al, 2013
Results of Intravenous Thrombolysis within 4.5 to 6 Hours and Updated Results within 3 to 4.5 Hours of Onset of Acute Ischemic Stroke Recorded in the Safe Implementation of Treatment in Stroke International Stroke Thrombolysis Register (SITS-ISTR)
JAMA Neurol 70:837-844, Ahmed, N.,et al, 2013
Thrombolysis for Ischemic Stroke Associated with Infective Endocarditis
Stroke 44:2917-2919, Asaithambi, G.,et al, 2013
Thrombolysis for Acute Ischemic Stroke in Patients with Cancer
Stroke 44:3573-3576, Murthy, S.B.,et al, 2013
The Argatroban and Tissue-Type Plasminogen Activator Stroke Study
Stroke 43:770-775,623, Barreto,A.D.,et al, 2012
Does Helicopter Emergency Medical Service Transfer Offer Benefit to Patients with Stroke?
Stroke 43:878-880, Olson,M.D. and Rabinstein,A.A., 2012
A Randomized Trial of Tenecteplase versus Alteplase for Acute Ischemic Stroke
NEJM 366:1099-1107, Parsons,M.,et al, 2012
Bridging Therapy in Acute Ischemic Stroke
Stroke 43:1302-1308, Mazighi,M.,et al, 2012
The Benefits and Harms of Intravenous Thrombolysis with Recombinant Tissue Plasminogen Activator within 6 h of Acute Ischaemic Stroke (the third international stroke trial IST-3): a Randomised Controlled Trial
Lancet 379: 2320, IST-3 collaborative group, 2012
Recombinant Tissue Plasminogen Activator for Acute Ischaemic Stroke: An Updated Systematic Review and Meta-Analysis
Lancet 379: 2364-2372, Wardlaw, J.M.,et al, 2012
Early Administration of Aspirin in Patients Treated with Alteplase for Acute Ischaemic Stroke: A Randomised Controlled Trial
Lancet 380:731-737, Zinkstok, S.M.,et al, 2012
Trevo Versus Merci Retrievers for Thrombectomy Revascularisation of Large Vessel Occlusions in Acute Ischaemic Stroke (TREVO 2): A Randomised Trial
Lancet 380:1231-1240,1208, Nogueira, R.G.,et al, 2012
Bridging Intravenous-Inta-Arterial Rescue Strategy Increases Recanalization and the Likelihood of a Good Outcome in Nonresponder Intravenous Tissue Plasminogen Activator-Treated Patients: A Case-Control Study
Stroke 42:993-997, 880, Rubiera,M.,et al, 2011
Intravenous thrombolysis in acute ischaemic stroke: a systematic review and meta-analysis to aid decision making in patients over 80 years of age
JNNP 82:712-717, Bhatnagar, P.,et al, 2011
Thrombolytic Treatment of Patients with Acute Ischemic Stroke Related to Underlying Arterial Dissection in the United States
Arch Neurol 68:1536-1542, Qureshi, A.I.,et al, 2011
Remote Supervision of IV-tPA for Acute Ischemic Stroke by Telemedicine or Telephone Before Transfer to a Regional Stroke Center Is Feasible and Safe
Stroke 41:e18-e24, Pervez,M.,et al, 2010
Time to Treatment With Intravenous Alteplase and Outcome in Stroke: An Updated Pooled Analysis of ECASS, ATLANTIS, NINDS, and EPITHET trials
Lancet 375:1695-1703, 1667, Lees, K.R., et al, 2010
Safety of Performing CT Angiography in Stroke Patients Treated With Intravenous Thrombolysis
JNNP 81:783-787, Aulick�,P., et al, 2010
Thrombolysis in Childhood Stroke: Report of 2 Cases and Review of the Literature
Stroke 40:801-807, Arnold,M.,et al, 2009
Thrombolysis in Young Adults with Ischemic Stroke
Stroke 40:2085-2091, Putaala,J.,et al, 2009
Number Needed to Treat to Benefit and to Harm for Intravenous Tissue Plasminogen Activator Therapy in the 3- to 4.5-Hour Window: Joint Outcome Table Analysis of the ECASS 3 Trial
Stroke 40:2433-2437,2295, Saver,J.L.,et al, 2009
Efficacy and Safety of Tissue Plasminogen Activator 3 to 4.5 Hours After Acute Ischemic Stroke: A Metaanalysis
Stroke 40:2438-2441, Lansberg,M.G.,et al, 2009
Intravenous Thrombolysis in Stroke Attributable to Cervical Artery Dissection
Stroke 40:37772-3776, Engelter,S.,et al, 2009
Endovascular Thrombectomy and Thrombolysis for Severe Cerebral Sinus Thrombosis: A Prospective Study
Stroke 39:1487-1490, Stam,J.,et al, 2008
Sonothrombolysis With Transcranial Color-Coded Sonography and Recombinant Tissue-Type Plasminogen Activator in Acute Middle Cerebral Artery Main Stem Occlusion: Results From a Randomized Study
Stroke 39:1470-1475,1404, Eggers,J.,et al, 2008
Local Intraarterial Fibrinolysis Administered in Aliquots for the Treatment of Central Retinal Artery Occlusion: The Johns Hopkins Hospital Experience
Stroke 39:1746-1750, Aldrich,E.M.,et al, 2008